Intron a, Introna(interferon alfa-2b)
Intron A, IntronA, Viraferon (interferon alfa-2b) is a protein pharmaceutical. Interferon alfa-2b was first approved as Intron a on . It is used to treat BCR-ABL positive chronic myelogenous leukemia, brain neoplasms, chronic hepatitis b, chronic hepatitis c, and colorectal neoplasms amongst others in the USA. It has been approved in Europe to treat BCR-ABL positive chronic myelogenous leukemia, carcinoid tumor, chronic hepatitis b, chronic hepatitis c, and follicular lymphoma amongst others.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| digestive system diseases | D004066 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| hemic and lymphatic diseases | D006425 |
| skin and connective tissue diseases | D017437 |
| endocrine system diseases | D004700 |
Show 2 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfa-2b
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Intron A | interferon alfa-2b | Merck Sharp & Dohme | N-103132 DISCN | 14 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| intron a | Biologic Licensing Application | 2020-12-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bcr-abl positive chronic myelogenous leukemia | EFO_0000340 | D015464 | — |
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| colorectal neoplasms | — | D015179 | — |
| condylomata acuminata | EFO_0007147 | D003218 | A63.0 |
| cryoglobulinemia | EFO_0005846 | D003449 | D89.1 |
| essential thrombocythemia | — | D013920 | D47.3 |
| hairy cell leukemia | — | D007943 | C91.4 |
| hemangioma | — | D006391 | D18.0 |
Show 21 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
interferon alfa-2b, Intron A, Merck Sharp & Dohme LLC | |||
| 2095-11-21 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0148 | Injection, pegylated interferon alfa-2b, 10 mcg |
Clinical
Clinical Trials
382 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 2 | 26 | 31 | 26 | 14 | 94 |
| Hepatitis c | D006526 | B19.2 | 5 | 17 | 21 | 13 | 6 | 56 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 11 | 14 | 6 | 2 | 3 | 32 |
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 4 | 8 | 11 | 5 | 7 | 31 |
| Neoplasms | D009369 | C80 | 8 | 5 | — | 1 | — | 13 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 4 | 1 | 3 | 8 |
| Hepacivirus | D016174 | — | 4 | 3 | 1 | 1 | 8 | ||
| Hepatitis b | D006509 | — | 2 | 2 | 1 | 3 | 8 | ||
| Hiv | D006678 | O98.7 | 1 | 1 | — | 2 | — | 4 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 2 | — | 1 | 1 | 4 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 13 | 14 | 10 | — | 1 | 36 | ||
| Renal cell carcinoma | D002292 | 3 | 12 | 3 | — | 1 | 16 | ||
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | 6 | 5 | — | — | 10 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 5 | 1 | — | — | 7 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | 2 | — | 1 | 5 |
| Polycythemia vera | D011087 | D45 | — | 1 | 3 | — | — | 4 | |
| Covid-19 | D000086382 | U07.1 | 2 | 3 | 1 | — | — | 3 | |
| Multiple myeloma | D009101 | C90.0 | — | 1 | 2 | — | — | 3 | |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | — | — | 3 | |
| Recurrence | D012008 | 1 | 3 | 2 | — | — | 3 |
Show 19 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 3 | — | — | — | 5 |
| Kaposi sarcoma | D012514 | C46 | 3 | 2 | — | — | — | 5 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 4 | — | — | — | 4 |
| Leukemia | D007938 | C95 | 2 | 1 | — | — | 1 | 3 | |
| Prostatic neoplasms | D011471 | C61 | — | 2 | — | — | — | 2 | |
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 | ||
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | — | — | 1 | 2 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 2 | — | — | — | 2 | |
| Carcinoma | D002277 | C80.0 | — | 1 | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | 1 | 4 | ||
| Triple negative breast neoplasms | D064726 | 2 | — | — | — | — | 2 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous substance abuse | D015819 | — | — | — | — | 1 | 1 | ||
| Lipodystrophy | D008060 | E88.1 | — | — | — | — | 1 | 1 | |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | — | — | 1 | 1 | |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Ascites | D001201 | HP_0001541 | R18 | — | — | — | — | 1 | 1 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INTERFERON ALFA-2B |
| INN | — |
| Description | Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980. It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon® Alfa R.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 99210-65-8 |
| RxCUI | 5880 |
| ChEMBL ID | CHEMBL1201558 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00105 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,338 documents
View more details
Safety
Black-box Warning
Black-box warning for: Intron a
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
75,177 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more